48 completed, 2 unknown, 1 terminated. 22 Phase 3, 7 Not applicable, 7 Phase 1, 7 Phase 2, 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Completed 21, Unknown 1 |
| Not applicable | 7 | Completed 7 |
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 7 | Completed 7 |
| Phase 4 | 7 | Completed 6, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Medy-Tox: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat MT921, Placebo - Submental Fat | Phase 3 | Completed | Medy-Tox | 240 | 2021-12-24 | 2023-02-23 |
| MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2 - Glabellar Lines, Lateral Canthal Lines | Phase 3 | Completed | Medy-Tox | 957 | 2019-10-23 | 2024-08-09 |
| Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® CORETOX Inj - Glabellar Frown Lines | Phase 4 | Unknown | Medy-Tox | 200 | 2019-10-17 | 2020-07-28 |
| A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat MT921, Placebo - Submental Fat | Phase 2 | Completed | Medy-Tox | 176 | 2019-09-10 | 2020-07-29 |
| Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder Neuronox, Placebo - Overactive Bladder | Phase 3 | Unknown | Medy-Tox | 216 | 2019-08-23 | 2020-07-28 |
| Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines MBA-P01(Botulinum toxin A), Placebo - Lateral Canthal Lines | Phase 2 | Completed | Medy-Tox | 150 | 2019-05-21 | 2021-03-19 |
| Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines MBA-P01 (Botulinum toxin A), Placebo - Glabellar Frown Lines | Phase 2 | Completed | Medy-Tox | 200 | 2019-05-20 | 2021-03-19 |
| Observational Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile Enhancement Penile Enhancement | Completed | Medy-Tox | 13 | 2019-04-10 | 2020-08-03 | |
| MT10109L in the Treatment of Glabellar Lines MT10109L, Placebo - Glabellar Lines | Phase 3 | Completed | Medy-Tox | 234 | 2018-12-24 | 2023-07-27 |
| MT10109L in the Treatment of Lateral Canthal Lines MT10109L, Placebo - Lateral Canthal Lines | Phase 3 | Completed | Medy-Tox | 235 | 2018-12-20 | 2023-10-05 |
| The Efficacy and Safety of Repeat-dose Potenfill for Temporary Penile Enhancement Potenfill - Penile Girth Enhancement, Penile Enhancement | Not applicable | Completed | Medy-Tox | 20 | 2018-12-17 | 2020-07-29 |
| The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines Cunox, Botox - Glabellar Frown Lines | Phase 3 | Completed | Medy-Tox | 136 | 2018-12-13 | 2020-07-29 |
| MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines MT10109L, Placebo - Lateral Canthal Lines, Glabellar Lines | Phase 3 | Completed | Medy-Tox | 425 | 2018-11-05 | 2023-07-17 |
| MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) MT10109L, Placebo - Glabellar Lines, Lateral Canthal Lines | Phase 3 | Completed | Medy-Tox | 415 | 2018-10-26 | 2023-05-25 |
| Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject LMT1-48, Placebo - Overweight | Not applicable | Completed | Medy-Tox | 97 | 2018-09-04 | 2020-07-28 |
| Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis Meditoxin, Placebo - Hyperhidrosis Primary Focal Axilla | Phase 3 | Completed | Medy-Tox | 220 | 2018-08-03 | 2020-07-28 |
| Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects MT921, Placebo - Healthy Volunteers | Phase 1 | Completed | Medy-Tox | 25 | 2018-07-31 | 2020-08-25 |
| Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-Face experimental, comparator - Mid Face Volume Loss | Not applicable | Completed | Medy-Tox | 236 | 2018-05-29 | 2021-03-19 |
| Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers MBA-P01, BOTOX - Healthy | Phase 1 | Completed | Medy-Tox | 28 | 2018-04-16 | 2019-03-26 |
| MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy Meditoxin, Placebo - Masseter Muscle Hypertrophy | Phase 3 | Completed | Medy-Tox | 180 | 2018-04-09 | 2020-07-28 |
Showing 20 of 51. Sign in to see all of them.
Muscle Spasticity (6) · Benign essential blepharospasm (2) · Masticatory Muscles, Hypertrophy of (2) · Neuralgia (2) · Torticollis (2) · Urinary Bladder, Overactive (2) · Dystonia (1) · Dystonic Disorders (1) · Hyperhidrosis (1) · Overweight (1) · Spinal Cord Injuries (1)
Botulinum Toxins, Type A (29) · coretox (4) · 3-deoxyglycero-galacto-nonulosonic acid (3) · Saline Solution (3) · Injections (1)
South Korea (33) · United States (5) · Australia (4) · Russia (4) · Canada (3) · Germany (3) · United Kingdom (3) · Belgium (2) · China (2)
SangMi Park (5) · BeomJoon Kim (2) · MyungEun Chung (2) · Beom Joon Kim, Ph D (1) · Beom Seon Gwon, Ph.D (1) · Beom-Joon Kim, MD, Ph.D. (1) · Chan Yeong Heo (1) · Chang-Hun Huh, MD, Ph.D. (1) · Eun S Park, Ph D (1) · Gwang Seong Choi, M.D., Ph.D. (1) · Hoon Kang (1) · Hoon Kang, M.D. (1) · Hoon Kang, MD, Ph.D. (1) · Huh Changhun, M.D. (1) · Jaechan Kim, M.D., Ph.D. (1)
PMID 12973229, PMID 19416246, PMID 26030192, PMID 26618119, PMID 32497599, PMID 32975061, PMID 35487505, PMID 884196, PMID 9463853
2014 (4), 2018 (1)